A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Phase: PHASE2
Conditions: Uncontrolled Hypertension, Chronic Kidney Diseases
Sponsor: AstraZeneca



5383,(5L"AF-JL;9@9,96L L
)I.<9>@)@L&'L L
	



"C-KL8@0:H08A498L
"C-KL9-0L
$0:>498L
(B0L
:4248(6L:9B9,96L(70L
#G7+0:L
?@=*080,(L
LD2E>@L	L
)I/:9>@)@L&'L
L
L
LD2E?BL
L
42B8L
L
#
L
		5
5	5
5')&$45
)/%%$'5%)	)'.+)%%5/%.$'.,5
+%%%+)/*5
)-'"$'"5./15.)50%/.5	5 )+5.#5
+.&'.5)!5.$'.-5$.#5')'.+)%%53*+.'-$)'5'5
	#+)($5$(25
$--5
" $ #($%#((((!#%('(
(&#(	
(
$M&18/?&41M'1M@$(>M4E/1@M(>M411@(,M1M(>M14?M?4MM(>,4>MJ(?$4E?M?$MJ8*@@1M41>1@M
4M	>C1MK5@M?4M?$MK?1?M@$?M(>,4>E8MJ4E-MM87E(8MLM,JM1M8M@$M5F854>M4M
H,F?(1"M148M41E@(1"MM-(1(-M>DLM8M	>@81M4EM8M,,4JM@4M(>,4>MAM41@1@>M
4M?$(>M4F02?M42,LM?4ML4G8M2>?(D?(42,MH&JM49M2M>DLM68>432,M(8?-LM(2H4,IMJ&@$M
42F?(2#M?%(>M684?44,M8>41>M?4MJ%40M?%M(2 <?)42M(>M(>.4>M0F>?MM&2 8/M?%?M?%M
)1 8/?)41M)>M411?(.M1M6846;)?=M?4M
>?;1M1M?%?M(?M0LM14?MM!%8M)>.4>M@4M
B(8M68@)>M
%)>M.(1(.MDLM84?44.M%>M1M>F+@M@4MM68M8I)JM48)1#M?4M
>@81M@18M
584G8>M%M-(1(.MDLM84?44.M)>M5F-).LM8")>@8M1M?$M8>F.?>M:M)>-4>M148M
6F.)>%M48)1#M?4M?%M
>@81M-4-M?18M )4?%)>M1M)1M406-)1MJ)?%M68I).)1#M
.J>M1M8#F.?)41>M
#LL ! !#!%L
L91L	L